Home
Resources
Publications
Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection

Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection

Alexandra D Mainiero, Dwight J Rouse, Vrishali Lopes, Brenna L Hughes

Obstet Gynecol. 2015 Jul;126(1):103-8.

PMID: 26241262

Abstract:

Objective:
To evaluate whether exposure to 17α-hydroxyprogesterone caproate is associated with the rate of peripartum infection in women who deliver preterm and their neonates.
Methods:
This is a retrospective cohort study of patients who delivered before 37 weeks of gestation at a tertiary care hospital between July 1, 2005, and December 31, 2012. Women in the case group (women exposed to 17α-hydroxyprogesterone caproate) were matched to women in a control group (unexposed patients) by gestational age and delivery date. The primary outcome was a composite infection rate comprising histologic or clinical chorioamnionitis, endometritis, or early-onset neonatal sepsis. To detect a 15% difference in composite infection rate between women exposed to 17α-hydroxyprogesterone caproate and those unexposed (two-tailed α=0.05 and power=80%), 183 patients per group were required. Logistic regression was performed to control for a history of prior spontaneous preterm birth and exposure to betamethasone.
Results:
The primary outcome frequency for women exposed to 17α-hydroxyprogesterone caproate was 34.6% (64 patients) compared with 33% (61 patients) in those unexposed (P=.74). There was no significant difference between women exposed to 17α-hydroxyprogesterone caproate and those unexposed in frequency of clinical chorioamnionitis (1.9% compared with 1.1%, P=.66), histologic chorioamnionitis (39.4% compared with 40%, P=.92), or early-onset neonatal sepsis (2.7% compared with 1.1%, P=.28). A total of 7.1% of women exposed to 17α-hydroxyprogesterone caproate developed endometritis compared with 2.7% of those unexposed (P=.05). The adjusted odds ratio for the primary outcome in women exposed to 17α-hydroxyprogesterone caproate was 0.65 (95% confidence interval 0.31-1.38).
Conclusion:
Exposure to 17α-hydroxyprogesterone caproate does not increase the risk of peripartum infection among women who deliver preterm or their neonates.
Level of evidence:
II.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP68962-A	17α-Hydroxyprogesterone		68-96-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: